Variable | Cox regression | Multinomial logistic regression | |||||
---|---|---|---|---|---|---|---|
Abnormal vs. normal | Thinness vs. normal | Overweight vs. normal | Â | ||||
HR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | Â | |
Demographic data | Â | Â | Â | Â | Â | Â | Â |
Male sex | 1.07 (0.61–1.66) | 0.979 | 0.85 (0.27–2.68) | 0.784 | 1.17 (0.53–2.58) | 0.690 |  |
Bahraini nationality | 0.3 (0.17–0.54) | < 0.001 | 58930879.04 | 1.000 | 3.98 (1.08–14.65) | 0.038 |  |
Normal delivery | 0.46 (0.1–2.12) | 0.316 | 22198171.35 | 1.000 | 0.16 (0.03–0.93) | 0.042 |  |
Crohn’s disease IBD type | 1.95 (1.18–3.23) | 0.009 | 1.21 (0.37–3.93) | 0.752 | 0.47 (0.22–0.99) | 0.048 |  |
Pre-diagnosis disease duration | 1.01 (0.96–1.06) | 0.725 | 1.05 (0.98–1.11) | 0.160 | 1.03 (0.97–1.09) | 0.332 |  |
Post-diagnosis disease duration | 0.0 (0.0–0.0) | < 0.001 | 1.02 (0.93–1.12) | 0.676 | 1.11 (1.04–1.17) | < 0.001 |  |
Age at presentation | 0.99 (0.93–1.05) | 0.694 | 0.86 (0.74–1.01) | 0.063 | 1.02 (0.91–1.13) | 0.769 |  |
Age at follow up | 0.81 (0.77–0.86) | < 0.001 | 0.97 (0.89–1.06) | 0.547 | 1.08 (1.03–1.13) | 0.002 |  |
Very early onset IBD | 0.42 (0.17–1.05) | 0.064 | 6.4 (1.57–26.15) | 0.010 | 1.92 (0.55–6.71) | 0.307 |  |
Clinical manifestation | Â | Â | Â | Â | Â | Â | Â |
Diarrhea | 0.52 (0.31–0.89) | 0.016 | 2.0 (0.51–7.83) | 0.320 | 1.67 (0.68–4.12) | 0.268 |  |
Recurrent abdominal pain | 1.09 (0.65–1.82) | 0.746 | 0.57 (0.18–1.78) | 0.334 | 0.8 (0.35–1.82) | 0.595 |  |
Weight loss | 1.7 (1.03–2.8) | 0.037 | 3.33 (0.86–12.92) | 0.082 | 0.37 (0.16–0.85) | 0.020 |  |
Pallor | 1.61 (0.97–2.67) | 0.067 | 0.96 (0.31–3.02) | 0.948 | 1.01 (0.45–2.25) | 0.991 |  |
Anorexia | 1.3 (0.8–2.13) | 0.296 | 0.96 (0.31–3.02) | 0.948 | 0.72 (0.32–1.65) | 0.441 |  |
Vomiting | 1.03 (0.61–1.74) | 0.903 | 1.43 (0.45–4.54) | 0.545 | 0.64 (0.26–1.59) | 0.340 |  |
Arthralgia | 1.12 (0.64–1.94) | 0.695 | 0.72 (0.18–2.87) | 0.642 | 0.99 (0.4–2.46) | 0.989 |  |
Perianal disease | 1.92 (1.06–3.45) | 0.031 | 1.14 (0.32–4.07) | 0.844 | 1.08 (0.43–2.69) | 0.873 |  |
Fever | 1.5 (0.81–2.78) | 0.198 | 0.63 (0.13–3.13) | 0.570 | 0.89 (0.32.-2.47) | 0.826 |  |
Constipation | 1.72 (0.89–3.32) | 0.107 | 0.77 (0.15–3.9) | 0.751 | 0.74 (0.24–2.3) | 0.597 |  |
Skin rash | 2.43 (1.26–4.69) | 0.008 | 0.0 (0.0–0.0) | 1.000 | 0.27 (0.06–1.29) | 0.101 |  |
Jaundice | 0.84 (0.31–2.32) | 0.739 | 2.39 (0.39–14.42) | 0.344 | 0.0 (0.0–0.0) | 1.000 |  |
Hematemesis | 1.5 (0.47–4.82) | 0.492 | 1.5 (0.15–15.51) | 0.734 | 0.55 (0.06–5.51) | 0.613 |  |
Extraintestinal manifestations | 1.44 (0.88–2.35) | 0.147 | 0.32 (0.08–1.24) | 0.098 | 0.8 (0.36–1.79) | 0.583 |  |
Disease activity at presentation | Â | Â | Â | Â | Â | Â | Â |
Moderate | 0.8 (0.43–1.48) | 0.474 | 1.93 (0.44–8.49) | 0.386 | 1.65 (0.58–4.69) | 0.346 |  |
Severe | 0.81 (0.44–1.48) | 0.490 | 1.27 (0.27–5.97) | 0.765 | 1.43 (0.5–4.05) | 0.507 |  |
Growth parameter | Â | Â | Â | Â | Â | Â | Â |
Birth weight | 1.57 (0.67–3.71) | 0.300 | 0.49 (0.13–1.85) | 0.289 | 1.03 (0.3–3.52) | 0.962 |  |
Weight at presentation | 0.99 (0.97-1.0) | 0.129 | 0.91 (0.84–0.98) | 0.015 | 1.06 (1.02–1.1) | 0.002 |  |
Height at presentation | 0.99 (0.98–0.99) | 0.041 | 0.97 (0.94-1.0) | 0.054 | 1.02 (0.99–1.05) | 0.070 |  |
BMI at presentation | 0.91 (0.86–0.98) | 0.009 | 1.16 (1.04–1.29) | 0.006 | 1.16 (1.04–1.28) | 0.005 |  |
Laboratory test | Â | Â | Â | Â | Â | Â | Â |
Hematocrit % | 0.99 (0.97–1.02) | 0.684 | 0.94 (0.89–0.99) | 0.034 | 1.0 (0.96–1.05) | 0.895 |  |
ESR | 1.0 (0.99–1.02) | 0.569 | 1.01 (0.98–1.04) | 0.554 | 1.0 (0.98–1.02) | 0.963 |  |
CRP | 1.0 (0.99–1.01) | 0.571 | 1.01 (0.99–1.02) | 0.128 | 0.99 (0.98–1.01) | 0.367 |  |
Medical therapy | Â | Â | Â | Â | Â | Â | Â |
Prednisolone | 1.94 (1.02–3.7) | 0.043 | 3.29 (0.39–27.55) | 0.271 | 0.57 (0.23–1.43) | 0.230 |  |
Azathioprine | 0.94 (0.55–1.61) | 0.823 | 115975454.6 | 1.000 | 0.89 (0.39–2.07) | 0.799 |  |
Mesalazine | 0.95 (0.58–1.57) | 0.848 | 0.8 (0.26–2.49) | 0.704 | 1.51 (0.66–3.46) | 0.326 |  |
Biological therapy | 0.66 (0.4–1.1) | 0.109 | 2.85 (0.87–9.31) | 0.084 | 1.23 (0.56–2.72) | 0.610 |  |
Exclusive enteral nutrition | 1.48 (0.64–3.43) | 0.360 | 1.62 (0.29–8.91) | 0.582 | 0.0 (0.0–0.0) | 1.000 |  |
Omeprazole | 1.14 (0.65-2.0) | 0.640 | 2.4 (0.49–11.77) | 0.280 | 0.71 (0.3–1.67) | 0.436 |  |
Folic acid | 1.44 (0.83–2.51) | 0.200 | 2.6 (0.53–12.7) | 0.238 | 0.77 (0.33–1.8) | 0.548 |  |
Iron supplementation | 1.36 (0.82–2.26) | 0.237 | 1.5 (0.46–4.9) | 0.502 | 1.17 (0.53–2.61) | 0.698 |  |
Vitamin D supplementation | 1.29 (0.78–2.13) | 0.323 | 1.88 (0.6–5.9) | 0.282 | 0.98 (0.44–2.16) | 0.957 |  |
Calcium supplementation | 0.68 (0.39–1.18) | 0.171 | 3.09 (0.97–9.83) | 0.056 | 1.92 (0.83–4.41) | 0.126 |  |
Multivitamins | 1.17 (0.68–2.02) | 0.576 | 3.47 (1.08–11.13) | 0.036 | 0.65 (0.26–1.63) | 0.358 |  |
Ursodeoxycholic acid | 0.98 (0.31–3.16) | 0.978 | 1.43 (0.14–14.78) | 0.765 | 0.5 (0.05–4.98) | 0.554 |  |
Fat soluble vitamins | 0.77 (0.19–3.18) | 0.722 | 2.18 (0.18–25.75) | 0.537 | 0.76 (0.07–8.7) | 0.827 |  |
Other medications | 0.35 (0.11–1.12) | 0.076 | 5.0 (0.9-27.82) | 0.066 | 2.78 (0.63–12.32) | 0.179 |  |